Insider Transactions in Q4 2023 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2023
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
239,023
-8.25%
|
$1,195,115
$5.08 P/Share
|
|
Nov 14
2023
|
Eric Devroe Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,450
-3.9%
|
$12,250
$5.08 P/Share
|
|
Nov 14
2023
|
Erick Gamelin Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-6.96%
|
$6,975
$5.08 P/Share
|
|
Nov 14
2023
|
Rasmus Holm Jorgensen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,470
-4.98%
|
$7,350
$5.08 P/Share
|
|
Nov 14
2023
|
Kristina Masson EVP - Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,900
-0.59%
|
$9,500
$5.08 P/Share
|
|
Nov 14
2023
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
735
-1.75%
|
$3,675
$5.08 P/Share
|
|
Oct 17
2023
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,232
-5.04%
|
$11,160
$5.48 P/Share
|